Amgen Licenses Erbitux-Related Patent After ImClone Court Loss
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen's competing anti-EGFR monoclonal antibody has Sept. 28 user fee date.
You may also be interested in...
ImClone, Sanofi-Aventis Settle Erbitux Patent Dispute
Each company will pay Israel’s Yeda $60 million, but ImClone also gains license for a patent critical to the production of cetuximab.
ImClone, Sanofi-Aventis Settle Erbitux Patent Dispute
Each company will pay Israel’s Yeda $60 million, but ImClone also gains license for a patent critical to the production of cetuximab.
ImClone Reports Promising Erbitux First-Line Colorectal Cancer Results
Company will present data from the Phase III CRYSTAL study at ASCO in June.